Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) completed its previously announced $5.5 million PIPE by consolidating remaining tranches into a single June 26, 2026 closing. Combined with approximately $2.8 million from warrant exercises in May, Akari received about $8.3 million in Q2 2026 to support upcoming clinical and regulatory milestones.
The company plans to use this added financial flexibility to advance AKTX-101 toward a Phase 1 first-in-human trial and progress its proprietary PH1 RNA splicing modulator ADC payload, including through potential strategic partnerships.
Positive
- Approximately $8.3 million total capital received in Q2 2026
- Completion of $5.5 million PIPE with remaining tranches consolidated into one closing
- About $2.8 million in additional proceeds from warrant exercises in May 2026
- Financing intended to support AKTX-101 advancement toward Phase 1 clinical trial
- Capital supports development of proprietary PH1 RNA splicing modulator ADC payload
Negative
- Issuance of Series H, I and J warrants remains subject to shareholder approval
- Private placement involves issuance of 1,470,588 ADSs or prefunded warrants, implying potential shareholder dilution
- Additional Series H, I and J warrants to purchase 1,470,588 ADSs each could further increase dilution if exercised
News Market Reaction – AKTX
In the Jun 29 session, AKTX declined 9.69%, reflecting a notable negative market reaction. Argus tracked a peak move of +17.7% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | ADC landscape update | Positive | +5.7% | CEO commentary on ADC landscape and plans for AKTX-101 Phase 1 timeline. |
| May 28 | Investor presentation | Positive | +38.5% | Virtual segment highlighting AKTX-101 potential and ASCO abstract acceptance. |
| May 21 | Preclinical data | Positive | +255.4% | Breakthrough preclinical synergy data for AKTX-101 with KRAS inhibition. |
| May 21 | Private placement | Positive | +49.9% | Announcement of $5.5M private placement to fund AKTX-101 development. |
| May 18 | Conference participation | Positive | +0.3% | Planned presentation on ADC pipeline at A.G.P.’s healthcare showcase. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AKTX has repeatedly posted strong positive price reactions to both scientific updates and financing news over the past six weeks.
Key Terms
pipe financial
prefunded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Consolidated closing of recently announced
TAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its previously announced PIPE through the consolidation of the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed in May, the Company received approximately
“We appreciate the decision of our investor group to complete the remaining funding earlier than originally scheduled, and for some of these investors to further increase their commitment through warrant exercises,” said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. “This additional capital is expected to provide added financial flexibility as we advance AKTX-101 towards a Phase 1 first-in-human clinical trial while advancing our proprietary PH1 RNA splicing modulator ADC payload through potential strategic partnerships.”
As previously announced, Akari entered into a securities purchase agreement with certain existing investors pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 1,470,588 ADSs or prefunded warrants to purchase ADSs together with Series H warrants, Series I warrants and Series J warrants to each purchase 1,470,588 ADSs.
Under the purchase agreement, the
Separately, during May 2026 the Company received approximately
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
